Review in Human gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 3 institutions in 1 country.
Tadatoshi SatoDepartment of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Sachin ChauguleDepartment of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Matthew B GreenblattResearch Division, Hospital for Special Surgery, New York, New York, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Jae-Hyuck ShimDepartment of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0002-4947-3293
University of Massachusetts Chan Medical School · USHarvard University · USHospital for Special Surgery · US
Funding
Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XUE, WEN · 2016 to 2020
$11.3M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
Novel approaches to promote healing of bone loss in inflammatory arthritisR01AR078230 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Ellen M Gravallese, Jae-Hyuck Shim · 2022 to 2026
$2.6M
"Establishing Pathways for Endothelial Support of Bone Formation with SLIT3"R01AR075585 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GREENBLATT, MATTHEW BLAKE · 2020 to 2024
$1.8M
Developing and evaluating bone targeting agents to mimic the skeletal effects of mechanical loadingR21AR079633 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SATO, TADATOSHI · 2022 to 2023
$457k
A novel bone-targeting AAV-mediated gene therapy to promote bone formation in osteoporosisR21AR077557 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SHIM, JAE-HYUCK · 2021 to 2022
The development of bone-targeting drug delivery systems holds immense promise for improving the treatment of skeletal diseases. By precisely delivering therapeutic agents to the affected areas of bone, these strategies can enhance drug efficacy, minimize off-target effects, and promote patient adherence, ultimately leading to improved treatment outcomes and an enhanced quality of life for patients. This review aims to provide an overview of the current state of affinity-based bone-targeting agents and recent breakthroughs in innovative bone-targeting adeno-associated virus (AAV) strategies to treat skeletal diseases in mice. In particular, this review will delve into advanced AAV engineering, including AAV serotype selection for bone targeting and capsid modifications for bone-specific tropism. Additionally, we will highlight recent advancements in AAV-mediated gene therapy for skeletal diseases and discuss challenges and future directions of this promising therapeutic approach.
Indexed as
Bone DiseasesDependovirusDrug Delivery SystemsGenetic TherapyGenetic VectorsAnimalsBone and BonesGene Transfer TechniquesHumansMicebisphosphonatebonerAAVtripeptide repeat of aspartate–serine–serine (DSS)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus. · full record | OpenQuestion